Trials / Completed
CompletedNCT04504279
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Forte Biosciences, Inc. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis. FB-401 will be applied topically for 16 weeks and progress will be assessed by assessment of the skin and patient reports.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | FB-401 | Topical application |
| BIOLOGICAL | Placebo | Vehicle |
Timeline
- Start date
- 2020-10-13
- Primary completion
- 2021-07-14
- Completion
- 2021-08-19
- First posted
- 2020-08-07
- Last updated
- 2021-09-16
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04504279. Inclusion in this directory is not an endorsement.